Payment overview · 2025
General Payments
$2,699.75
39 reported records · 11 companies
Healthcare provider profile · identity verified
Ling Lu
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1447562376
Verified facts
What the public records show
CMS Open Payments records show Ling Lu received $2,699.75 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Vemlidy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $994.90 | 36.9% | 15 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $638.83 | 23.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $199.15 | 7.4% | 5 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $165.85 | 6.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.00 | 5.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $150.00 | 5.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $125.00 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 4.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $64.59 | 2.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.15 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.28 | 1.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,699.75 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $638.83 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $376.52 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $353.11 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $265.27 | 8 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $165.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $142.07 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $64.59 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 57 |
| Donepezil Hcl | Donepezil Hcl | 199 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 46 |
| Vascepa | Icosapent Ethyl | 187 | 52 |
| Gabapentin | Gabapentin | 176 | 51 |
| Losartan Potassium | Losartan Potassium | 176 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 19 |
| Eliquis | Apixaban | 125 | 18 |
| Metformin Hcl | Metformin Hcl | 114 | 30 |
| Trazodone Hcl | Trazodone Hcl | 106 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 23 |
| Omeprazole | Omeprazole | 100 | 45 |
| Finasteride | Finasteride | 96 | 23 |
| Meclizine Hcl | Meclizine Hcl | 89 | 46 |
| Simvastatin | Simvastatin | 82 | 18 |
| Diclofenac Epolamine | Diclofenac Epolamine | 79 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 37 |
| Buspirone Hcl | Buspirone Hcl | 77 | 16 |
| Januvia | Sitagliptin Phosphate | 74 | 14 |
| Alendronate Sodium | Alendronate Sodium | 69 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 15 |
| Azithromycin | Azithromycin | 64 | 43 |
| Farxiga | Dapagliflozin Propanediol | 62 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 13 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Furosemide | Furosemide | 60 | 16 |
| Lactulose | Lactulose | 60 | 16 |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 13 |
| Carvedilol | Carvedilol | 57 | 12 |
| Jardiance | Empagliflozin | 56 | suppressed |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Olanzapine | Olanzapine | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Levetiracetam | Levetiracetam | 51 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 47 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 28 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 45 | 15 |
| Meloxicam | Meloxicam | 44 | 26 |
| Risperidone | Risperidone | 44 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 42 | 33 |
| Nifedipine Er | Nifedipine | 42 | 11 |
| Potassium Chloride | Potassium Chloride | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 23 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 18 |
| Amoxicillin | Amoxicillin | 36 | 26 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 36 | 25 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Haloperidol | Haloperidol | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 12 |
| Azelastine Hcl | Azelastine Hcl | 31 | 21 |
| Celecoxib | Celecoxib | 30 | 18 |
| Metformin Hcl Er | Metformin Hcl | 30 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Lisinopril | Lisinopril | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Prednisone | Prednisone | 26 | 13 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 25 | 19 |
| Linzess | Linaclotide | 25 | 12 |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 11 |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 12 |
| Ketoconazole | Ketoconazole | 18 | 13 |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,699.75 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, LINZESS, MYFEMBREE, OTEZLA, PROLIA, REPATHA, REZDIFFRA, Senza, VOQUEZNA, Vemlidy, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error